Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|April 15, 2002
PDT trials aim to extend knowledge from TAP, VIP studies
Baltimore-Ocular photodynamic therapy (PDT) using verteporfin (Visudyne, Novartis) already has been shown to be beneficial in the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
3
Anti-VEGF switches for persistent fluid: A review of 3 clinical cases
4
Inflammasome inhibition with K8 in geographic atrophy: A Q&A
5